Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase III trial on Onconase combination initiated

Aug. 30, 1996

New agents for use in transplantation

Aug. 30, 1996

Aviron's intranasal influenza vaccine begins phase III

Aug. 30, 1996

FDA approval requested for thymoglobin manufacturing process, facility

Aug. 30, 1996

Superoxide ion production inhibitors from Sagami

Aug. 30, 1996

VLA-4 receptor-blocking drugs described by Zeneca

Aug. 30, 1996

Protease inhibitors described by Shionogi

Aug. 30, 1996

Gene mutancy linked to natural HIV-1 infection resistance

Aug. 30, 1996

Genetic sequence of AIDS-related disease revealed

Aug. 30, 1996

Cytel receives phase I SBIR grant for AIDS vaccine development

Aug. 30, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Latus Bio series A financing supports early-stage programs
BioWorld Science
Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the...